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Aims: Levels of the endothelium-derived peptide endothelin-1 (ET-1) are elevated in obese humans, and ET-1
mediated vascular tone is increased. Renal arterial smooth muscle is highly responsive to ET-1. Whether or not
endothelium-derived ET-1 affects contractions of the renal artery under normal conditions or in obesity is un-
known. The present study was designed to investigate whether or not overexpression of endogenous ET-1 in
the endothelium affects the responsiveness of the main and segmental renal arteries differently in obesity.
Main methods: Mice with tie-1 promoter-driven endothelium-restricted heterozygous overexpression of
preproendothelin-1 were used (TEThet). Obesity was induced in TEThet mice and wild-type (WT) littermates by
feeding a high fat diet for 30 weeks; lean controls were kept on standard chow. The renal arteries were studied
in wire myographs testing contractions (in the presence of L-NAME) to ET-1, serotonin, and U46619.
Key ﬁndings:Contractions to ET-1were comparable between groups inmain renal arteries, but augmented in seg-
mental preparations from obese mice. Serotonin-induced responses were enhanced in obese TEThet mice renal
arteries compared to lean controls. Concentration–contraction curves to U46619 were shifted signiﬁcantly to
the left in main renal arteries of obese animals, and the maximal response was signiﬁcantly increased between
lean and obese TEThet mice.
Signiﬁcance: These results indicate an augmented responsiveness of main renal arteries in obesity particularly to
TP receptor activation. When combined with endothelial ET-1 overexpression this effect is even more pro-
nounced, which may help to gain further insights into the mechanisms of hypertension in obesity.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Kidneys play a key role in the homeostasis of salts and water and in
the development of hypertension (Guyton et al., 1972). A reduction in
renal perfusion leads to increased blood pressure (Goldblatt et al.,
1934; Hall, 2003). The potent vasoconstrictor peptide endothelin-1
[ET-1 (Yanagisawa et al., 1988)] has been implicated in renal disease
leading to high arterial blood pressure (Kohan et al., 2011). However,
renal overexpression of either ET-1 or ET-2 does not cause hypertension
per se (Hocher et al., 1996, 1997; Shindo et al., 2002). Nevertheless, suchg, Department of Pharmacology
F Laboratory Block, 21 Sassoon
.
. This is an open access article undertransgenic animals are prone to developing kidney ﬁbrosis and salt-
dependent hypertension (Hocher et al., 1997; Liefeldt et al., 1999;
Shindo et al., 2002).
Obesity due to the imbalance between excessive calorie intake
and reduced physical activity is one of the emerging global health is-
sues and is associated with an activated endothelin system in
humans with or without hypertension (Cardillo et al., 2004; Weil
et al., 2011). The impact of obesity on responsiveness in the renal
vascular bed is largely unknown. Therefore, the present experiments
were designed to compare vasoconstrictor responses to ET-1, the
platelet product serotonin and the thromboxane prostanoid (TP) re-
ceptor agonist U46619 in isolated main and segmental renal arteries
of lean and obesemice. To determinewhether or not increased levels
of endothelial ET-1 would affect these responses, preparations from
animals with heterozygous endothelium-restricted overexpressionthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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with those of wild-type (WT) littermates.
Materials and methods
Animals
Male mice with heterozygous endothelial overexpression of the mu-
rine preproET-1 cDNA (Leung et al., 2004) (TEThet) and wild-type (WT)
littermates on a C57BL/6N backgroundwere housed in the laboratory an-
imal unit at constant temperature under a 12 h light–dark cycle with free
access towater anddiet. Obesitywas induced by ahigh fat diet (D12079B,
Research Diets Inc., New Brunswick, NJ, USA) for 30 weeks (Traupe et al.,
2002; Mundy et al., 2007), and lean control animals were kept on stan-
dard rodent chow (D5053, Lab Diet, Purina Mills, Richmond, IN, USA).
The salt content was approximately 0.75% in the standard and 0.25% in
the high fat diet. On the day of experiments mice were anesthetized
with a mixture of fentanyl citrate (0.4 mg/kg), and ﬂuanisone (12.5 mg/
kg) plus midazolam (6.25 mg/kg) prior to exsanguination by cardiac
puncture. Procedures were performed in accordance with the Guide for
the Care andUse of Laboratory Animals issued by the U.S. Institute of Lab-
oratory Animal Research (ILAR, eighth edition, 2011) and were approved
by the institutional Committee on the Use of Live Animals for Teaching
and Research of the University of Hong Kong.
Blood pressure and body fat
Systolic arterial blood pressure was determined non-invasively by
the tail-cuff method (BP-2000 Blood Pressure Analysis System, Visitech
Systems Inc., Raleigh, NC, USA) at the end of the study in conscious an-
imals, following a training period of ﬁve days; such determination
shows a high correlation with invasive measurements in unrestrained,
unanesthetizedmice (Krege et al., 1995). Body fatmasswas determined
in conscious mice by time-domain NMR spectroscopy (Minispec model
LF90II, Bruker Instruments, Billerica, MA, USA).
Tissue harvesting and preparation
After sacriﬁce, the main renal arteries were dissected free of
perivascular adipose and connective tissue. Rings of the left and right
main and of segmental [ﬁrst branch] renal arteries were suspended
between 40 μM stainless steel wires in Halpern–Mulvany myographs
(models 610 M and 620 M, Danish Myo Technology A/S, Aarhus,
Denmark) ﬁlled with modiﬁed Krebs–Ringer bicarbonate solution [in
mmol/L: NaCl, 129; KCl, 4.7; KH2PO4, 1.18; MgSO4, 1.17; NaHCO3, 14.9;
glucose, 5.5; calcium disodium EDTA, 0.026; CaCl2, 2.5 (control solution)]
permitting to achieve a stable pH of 7.4 in the covered and aerated [95%
O2 plus 5% CO2] chambers (Baretella et al., 2013). The preparations
were equilibrated at 37° C for 30 min prior to the ﬁrst application of
force (1 mN). For each individual ring every following 1 mN increase in
tensionwas followed by replacement of the control solution for a fewmi-
nutes with an iso-osmotic high potassium solution (60 mmol/L high K+
with equimolar substitution of sodium by potassium). The high K+
solution was washed out after the induced response has exceeded or
was similar in amplitude to the preceding high K+ contraction resulting
in an active tension–tension relationship (Vanhoutte and Leusen, 1969;
Baretella et al., 2013). The response to the ﬁnal depolarization with
60 mmol/L high K+ was allowed to plateau, which occurred within two
(segmental arteries) to ten (main renal arteries) minutes. This submaxi-
mal response was used as reference contraction.
Functional protocols
In order to exclude any effects of nitric oxide (NO), whichmodulate
both the production and the action of ET-1 (de Nucci et al., 1988;
Boulanger and Lüscher, 1990; Vanhoutte, 2000; Félétou et al., 2012)and the release of which could be initiated by ET-1 or serotonin acting
on ETB or 5-HT1D receptors, respectively (Cohen et al., 1983; de Nucci
et al., 1988; Schoeffter and Hoyer, 1990; Schini et al., 1991; Hirata
et al., 1993), all experiments were performed in the presence of a NO
synthase inhibitor. The rings were equilibrated for at least ten minutes
prior to incubation with the non-selective nitric oxide synthase
inhibitor Nω-nitro-L-arginine methyl ester (L-NAME, 3 × 10−4 mol/L)
for 30 min to block basal and receptor-stimulated generation of NO
(Widmer et al., 2006; Baretella et al., 2013). The left renal artery was
exposed to a full concentration-response curve of serotonin (10−10 to
3 × 10−5 mol/L); rings of the right renal artery were contracted with
ET-1 (10−11 to 10−7 mol/L) and U46619 (10−11 to 3 × 10−6 mol/L).
If consecutive contractions were obtained with different agonists,
the preparations were relaxed maximally with sodium nitroprusside
(10−5 mol/L), followed by several washouts prior to re-incubation
with L-NAME and addition of the next drug.
Drugs
Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME), serotonin
and sodium nitroprusside were purchased from Sigma-Aldrich
(St. Louis, MO, USA); 9,11-Dideoxy-9α,11α-methanoepoxy prostaglan-
din F2α (U46619) and endothelin-1 (ET-1) were from Enzo Life Sciences
(Farmingdale, NY, USA). All drugswere dissolved indistilledwater except
U46619, which was dissolved in ethanol (10−2 mol/L; ﬁnal concentra-
tions in the myograph chamber not exceeding 0.1%). Stock solutions for
ET-1 (10−5 mol/L) were dissolved in 5% acetic acid (100 μl aliquots).
Concentrations are given as ﬁnal molar concentration in the myograph
chamber solution.
Statistical analysis
All contractions are expressed as percentage of the reference contrac-
tion to 60 mmol/L high K+. Maximal contractions (Emax) and concentra-
tions causing half maximal responses (EC50; shown as pD2 values) were
calculated and compared using nonlinear regression analysis in Prism
version 5 (GraphPad Software Inc., San Diego, CA, USA). Data were tested
for distribution normality using the D'Agostino–Pearson test. Student's
t-test for unpaired observations or the Mann–Whitney U test were ap-
plied to analyze statistical differences between groups of normally dis-
tributed or non-parametric samples, respectively. Two-way analysis of
variance (ANOVA) for multiple comparisons followed by Bonferroni
post hoc test was used where appropriate. Results are shown as
means ± standard error of the mean (SEM), and n equals the number
of preparations from different animals. P values smaller than 0.05
were considered to indicate statistically signiﬁcant differences.
Results
Obesity development and blood pressure
All animals on high fat diet had developed obesity after
30 weeks treatment compared to lean mice kept on standard
chow (fat mass: 5.4 ± 0.7 g in lean WT, 5.5 ± 0.7 g in lean TEThet
mice, 15.4 ± 0.5 g in obese WT and 16.8 ± 0.7 g in obese TEThet).
Systolic arterial blood pressure did not differ signiﬁcantly irrespective of
genotype between lean and obese animals and was within normal limits
(lean WT: 107.1 ± 2.3 mm Hg, lean TEThet: 103.7 ± 2.8 mm Hg, obese
WT: 116.1 ± 4.4 mm Hg, obese TEThet: 105.7 ± 3.5 mm Hg).
Functional studies
Submaximal contractions to potassium chloride (60 mmol/L high
K+) averaged 6.9 ± 0.6 mN for the left and 8.5 ± 0.5 mN in the right
main renal artery; these reference contractions were comparable be-
tween groups (data not shown). The reference contractions of
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Fig. 1. Contractions to endothelin-1 in main renal artery rings of lean and obese wild-type (WT; A) mice and littermates with endothelial overexpression of the preproET-1 gene in the
endothelium (TEThet; B), and responses in segmental renal artery rings of WT (C) and TEThet mice (D). All experiments were in the presence of L-NAME (3 × 10−4 mol/L). Values are
means ± SEM; n = 6–10. *P b 0.05 vs lean controls.
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increases in tension were observed in rings of either lean or obese WT
and TEThet mice during incubations with L-NAME.
Endothelin-1
Endothelin-1 (ET-1) caused potent concentration-dependent
increases in tension of both main and segmental renal arteries (Fig. 1,Table 1
Efﬁcacy (Emax) and potency (pD2 of pharmacological responses in main renal arteries of lean an
(3 × 10−4 mol/L). Emax (efﬁcacy) expressed as %high K+ and pD2 (potency) as negative logari
Responsiveness of main renal arteries
Agonist WT
Lean Obese
Endothelin-1 Emax 109.0 ± 2.8 107.6 ± 6.7
pD2 8.3 ± 0.1 8.4 ± 0.1
Serotonin Emax 90.0 ± 1.4 90.1 ± 1.4
pD2 7.1 ± 0.1 7.1 ± 0.1
U46619 Emax 128.2 ± 2.2 131.6 ± 2.5
pD2 8.3 ± 0.1 8.5 ± 0.1Table 1). After the addition of the ﬁnal concentration, the contractile re-
sponse to ET-1was not sustained in preparations of both lean and obese
mice, as previously described for leanmice (Widmer et al., 2006). There
was no signiﬁcant difference in the response to the vasoconstrictor pep-
tide betweenmain renal arteries of lean and obeseWT (Fig. 1A, Table 1)
and TEThet (Fig. 1B, Table 1) mice. In the segmental rings fromWTmice,
contractions to lower concentrations of ET-1 were signiﬁcantly in-
creased but maximal responses (Emax) signiﬁcantly reduced by obesityd obeseWT and TEThetmice). All experiments were conducted in the presence of L-NAME
thm of EC50. Values are means ± SEM.
TEThet
P value Lean Obese P value
0.83 115.6 ± 5.9 110.3 ± 4.2 0.46
0.22 8.2 ± 0.1 8.3 ± 0.1 0.42
0.97 87.3 ± 0.8 95.2 ± 2.3 b0.01
0.31 7.1 ± 0.1 7.2 ± 0.1 b0.05
0.32 120.4 ± 2.9 138.2 ± 3.7 b0.001
b0.001 8.2 ± 0.1 8.6 ± 0.1 b0.001
209O. Baretella et al. / Life Sciences 118 (2014) 206–212(Fig. 1C, Table 2). Endothelial overexpression of preproET-1 itself had no
effect on contractions to the peptide in both arteries of lean animals;
obesity augmented contractions to ET-1 only in TEThet segmental renal
arteries (Fig. 1D, Table 2).Serotonin
Serotonin also caused concentration-dependent contractions of
the renal arteries (Fig. 2). These responses were again not sustained
and faded away following the addition of the highest concentration
of the monoamine (data not shown). Responses to serotonin were
not signiﬁcantly different in main renal arteries of lean and obese
WT mice (Fig. 2A). Obesity lowered the maximal responsiveness to
the monoamine signiﬁcantly in segmental renal arteries of WT
mice (Fig. 2C, Table 2). Both types of preparations of lean animals
with endothelial cell-speciﬁc overexpression of the preproET-1
gene contracted equally in response to serotonin as those from
their WT littermates (Tables 1 and 2). The monoamine caused signif-
icantly larger contractions in main renal arteries of obese than in
those of lean TEThet mice (Fig. 2B, Table 1). In both types of renal
arteries of obese TEThet mice the concentration-response curve to
serotonin was slightly but signiﬁcantly shifted to the left compared
to that of lean controls (Fig. 2B and D, Tables 1 and 2). Moreover, in
TEThet preparations the maximal contraction of segmental renal
artery rings to serotonin was signiﬁcantly larger than in those of
obese WT mice (Fig. 2C and D).TP receptor agonist
Contractions to the full thromboxane prostanoid (TP) receptor ago-
nist U46619 (Kiriyama et al., 1997) were signiﬁcantly larger than those
to ET-1 and serotonin in renal artery rings, exceeding responses to
60 mmol/L potassium chloride (Fig. 3). By contrast to ET-1 and
serotonin-induced contractions, the responses to higher concentrations
of U46619 were sustained (data not shown). The concentration–con-
traction curve to the compound was shifted signiﬁcantly to the left in
main, but not in segmental renal arteries fromobeseWTmice only com-
pared to those of lean animals (Fig. 3A, Table 1). Endothelial cell-speciﬁc
overexpression of the preproET-1 gene had no effect on the potency of
U46619 in main renal arteries of lean animals, but the maximal re-
sponse was reduced compared to WT littermates (Fig. 3A and B,
Table 1). By contrast, with obesity the maximal response to U46619
was augmented signiﬁcantly in main renal artery preparations from
obese compared to lean TEThet mice in addition to a signiﬁcant shift to
the left of the concentration–response curve (Fig. 3B, Table 1). Re-
sponses to the thromboxane A2 analog were unaffected by obesity and
endothelial overexpression of preproET-1 in segmental renal artery
rings (Fig. 3C and D, Table 2).Table 2
Efﬁcacy (Emax) and potency (pD2 of pharmacological responses in segmental renal arteries of l
NAME (3 × 10−4 mol/L). Emax (efﬁcacy) expressed as %high K+ and pD2 (potency) as negative
Responsiveness of segmental renal arteries
Agonist WT
Lean Obese
Endothelin-1 Emax 124.6 ± 2.7 107.3 ± 2.5
pD2 8.4 ± 0.1 8.6 ± 0.1
Serotonin Emax 111.0 ± 2.8 99.5 ± 3.0
pD2 7.4 ± 0.1 7.5 ± 0.1
U46619 Emax 135.3 ± 2.2 130.3 ± 3.1
pD2 8.8 ± 0.1 8.7 ± 0.1Discussion
The key ﬁndings of the present study are that, in the two sizes of
renal arteries tested, potent contractions to ET-1 are obtained which
are comparable between main renal artery rings of lean and obese ani-
mals, irrespective of the heterozygous overexpression of preproET-1 in
endothelial cells. Contractions to serotoninwere somehowmore potent
in renal arteries of obese TEThet mice. By contrast to these modest
changes, contractions to the full range of concentrations of the TP recep-
tor agonist U46619were potentiated not in segmental but inmain renal
arteries of animals with diet-induced obesity, especially in those of the
obese TEThet mice.
Blood vessels of obese animals contain an increased ET-1 gene expres-
sion and ETA receptor protein presence, but the effect of increased body
weight on the responsiveness to the vasoconstrictor peptide is not ho-
mogenous among murine conduit arteries (Traupe et al., 2002; Mundy
et al., 2007). ET-1 is less efﬁcacious in inducing contractions in aortae or
carotid arteries of C57BL/6 mice as compared to their main renal artery
(Widmer et al., 2006). Contractions to ET-1 are more pronounced in seg-
ments of the right renal arteries of spontaneously hypertensive than in
those of normotensive control rats (Tomobe et al., 1988). This rodent
model of hypertension exhibits greater sensitivity to vasoconstrictor ago-
nists early on in the disease (Lais and Brody, 1978; Chatziantoniou et al.,
1990; Ge et al., 1995, 1999). Since ET-1 and NO are opposing players in
the local control of vascular tone (de Nucci et al., 1988; Boulanger and
Lüscher, 1990; Vanhoutte, 2000; Hocher et al., 2004; Félétou et al.,
2012), the present experiments were performed in the systematic pres-
ence of a NO synthase inhibitor to fully focus on vascular smooth muscle
responsiveness to the agonists tested. This experimental setting ex vivo
may also mimic pathophysiological situations in vivo [e.g. salt-sensitive
hypertension (Barton et al., 2000)],whereNO synthase activity is reduced.
The contractions to ET-1were identical inmain renal arteries of lean
and obesemicewhether or not preproET-1 overexpressionwas present,
suggesting that the response to the vasoconstrictor peptide is not
altered by obesity in this preparation. By contrast, obesity ampliﬁed
responses especially in TEThet segmental renal artery rings. This is in
contrastwith previous studies on other arteries inmicewith endothelial
overexpression of the human or murine ET-1 gene, where contractions
to ET-1 were lower in certain arteries of the transgenic animals
compared to wild-type controls (Amiri et al., 2004; Leung et al., 2011;
Javeshghani et al., 2013). Presumably, these experimentswere conduct-
ed in preparations with endothelium and without NO synthase
inhibition, and thus NO release resulting from activation of endothelial
ETB receptors may have confounded the results (Hirata et al., 1993).
An increased ETB receptor expression has been demonstrated for
endothelium-restricted overexpression of ET-1 (Amiri et al., 2004).
However, the augmented contractions to ET-1 in segmental renal artery
rings observed in the present study with obesity, particularly when
combined with an up-regulated ET-1 system, could be an indicator for
circulatory mechanisms deeper inside the kidney, which would be ofean and obese WT and TEThet mice). All experiments were conducted in the presence of L-
logarithm of EC50. Values are means ± SEM.
TEThet
P value Lean Obese P value
b0.001 117.8 ± 3.5 109.1 ± 3.9 0.14
b0.001 8.5 ± 0.1 8.8 ± 0.1 b0.001
b0.01 110.9 ± 2.1 115.5 ± 1.5 0.09
0.47 7.4 ± 0.1 7.6 ± 0.1 b0.01
0.20 133.4 ± 2.2 126.4 ± 4.0 0.13
0.98 8.8 ± 0.1 9.0 ± 0.1 0.06
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Fig. 2.Responses to serotonin in preparations of themain renal artery of lean and obesewild-type (WT; A)mice and littermateswith endothelial overexpression of the preproET-1 gene in
the endothelium (TEThet; B), and contractions in segmental renal artery rings ofWT (C) and TEThetmice (D). All experimentswere in the presence of L-NAME (3 × 10−4 mol/L). Values are
means ± SEM; n = 4–9. *P b 0.05 vs lean controls, †P b 0.05 vs obese WT.
210 O. Baretella et al. / Life Sciences 118 (2014) 206–212pathophysiological relevanceunder these conditions (Hall, 2003; Kohan
et al., 2011; Schildroth et al., 2011).
Serotonin is also a potential regulator of arterial blood pressure
(Vanhoutte, 1985; Watts et al., 2012). It evoked pronounced contrac-
tions in renal arteries of lean and obese WT mice. Endothelial overex-
pression of ET-1 had no effect on the reactivity in rings from lean
animals, but the responses to the monoamine of both main renal and
segmental arteries of obese TEThet mice were potentiated. The ﬁnding
that a moderate up-regulation of the ET-1 system facilitates contrac-
tions to serotonin in obesity is compatible with the demonstration
that low concentrations of ET-1 augment the response to the mono-
amine in human arteries (Yang et al., 1990). Serotonin also induced
greater contractions in perfused kidneys of spontaneously hypertensive
compared to normotensive rats (Collis and Vanhoutte, 1977). The
contractions faded upon the addition of the highest concentrations of
serotonin in both main and in segmental renal artery rings illustrating
the tachyphylaxis developing with cumulative concentrations of
the substance (Collis and Vanhoutte, 1977). A delayed onset of
tachyphylaxis in segmental preparations of the TEThet compared to
WT mice in obesity could explain why contractions to serotonin were
potentiated in the former but reduced only in the latter compared to
rings from lean controls.Such tachyphylaxis apparently was not present in response to
higher concentrations of the thromboxane prostanoid (TP) receptor ag-
onist U46619 (Quilley and McGiff, 1990b) inducing sustained contrac-
tions in contrast to the transient responses obtained with high
concentrations of either ET-1 or serotonin. Obesity had no obvious effect
on TP receptor sensitivity in segmental preparations, but in the more
proximal main renal arteries of obese animals, U46619 was more
potent. By contrast, in main renal arteries of the spontaneously hyper-
tensive rat, contractions to the TP receptor agonist are comparable to
those in normotensive control animals (Michel et al., 2008). In rings of
mouse main and interlobar renal arteries exposed to high glucose,
increased responses to U46619 were observed in the latter but not in
the former (Nobe et al., 2008). Differences in segmental responsiveness
may possibly result from variations in the experimental settings includ-
ing the strain ofmice used (Nobe et al., 2008). The present leftward shift
of the concentration-response curve to U46619 observed in main renal
artery rings from diet-induced obese compared to lean control animals
resembles the augmented responsiveness to the TP receptor agonist in
corresponding preparations of rats with type 2 diabetes (Matsumoto
et al., 2013). Renal arteries of type 1 diabetic rats also exhibit a greater
responsiveness to the thromboxane analog compared to the prepara-
tions from normoglycemic animals — an effect curtailed by endothelin
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Fig. 3. Contractions to the TP receptor agonist U46619 inmain renal artery preparations of lean and obese wild-type (WT; A)mice and littermates with endothelial overexpression of the
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supporting the present ﬁndings of potentiated contractions to U46619
particularly in main renal artery branches of obese TEThet mice.
In the present study, no elevations of systolic arterial blood pressure
were found in TEThet mice (whether lean or obese). The systolic and
mean arterial pressure of the homozygous genotype of this animal is el-
evated and can be reduced by an ETA receptor antagonist (Leung et al.,
2011). This difference is explained best by the reduced up-regulation
of the ET-1 system in the TEThet mice used in the present experiments.
In view of the lack of manifest changes in systolic arterial blood pres-
sure, the hyperresponsiveness to U46619 in isolatedmain renal arteries
can be compared with the increased reactivity to TP receptor activation
reported in young rats developing hypertension (Chatziantoniou et al.,
1990).
Responses to ET-1 vary with age, the vascular preparation studied,
the animal model investigated, the experimental techniques applied,
and the level of arterial blood pressure (Tomobe et al., 1988; Miller
et al., 1989; Seo and Lüscher, 1995; Inscho et al., 2005; Schildroth
et al., 2011). At the microcirculatory level within the kidney, contrac-
tions to ET-1 itself may differ e.g. being stronger in afferent than that
in efferent arterioles and the relative involvement of endothelin
receptor subtypes mediating contractions to the peptide can vary aswell e.g. with ETB receptors contributing to vasoconstriction in efferent
arterioles (Schildroth et al., 2011). The present experiments, limited to
larger renal arteries outside the kidney, demonstrate, in normotensive
animals, moderate increases in vascular smooth muscle responsiveness
induced by obesity alone that are ampliﬁed by endothelial ET-1
overexpression.
Conclusion
The present ﬁndings imply that obesity – in particular in the pres-
ence of an up-regulated endothelial ET-1 system – potentiates the re-
sponsiveness of the vascular smooth muscle of main and/or segmental
renal arteries to agonists such as serotonin and thromboxane analogs.
Thereby, ET-1 functions rather as a modulator than a direct effector as
suggested by the present results with exogenous administration of the
vasoconstrictor peptide inmain renal arteries. If these changes observed
in the main branches of the renal artery reﬂect those occurring at the
level of the renal microcirculation (e.g. in preglomerular resistance ves-
sels), this may result in decreased blood ﬂow in vivo favoring the devel-
opment of hypertension. In that respect, an increase in endothelial ET-1
may contribute to arterial blood pressure elevation in obesity via an
augmentation in renal vascular tone.
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